• About Us
Medivation recognizes the importance of collaborations to maximize the global potential of our product candidates.

In October 2009, Medivation and Astellas entered into a global agreement to jointly develop and commercialize enzalutamide. The companies are collaborating on a comprehensive development program that includes studies to develop enzalutamide across the full spectrum of advanced prostate cancer as well as advanced breast cancer. The companies jointly commercialize XTANDI in the U.S. and Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI outside the U.S. Astellas will pay us a tiered royalty ranging from the low teens to the low twenties on any aggregate net sales of XTANDI outside the U.S.